Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Comment on ‘The effect of erythropoietin on the severity of retinopathy of prematurity’


We read with interest the article ‘The effect of erythropoietin on the severity of retinopathy of prematurity’.1 Even if the results are interesting, we have a few concerns and comments. The use of sedatives to screen all the babies for ROP is surprising and can be risky for these vulnerable infants.2 The babies with stage 3 ROP were treated when they reached threshold stage despite ETROP recommendation3 to treat babies, at high risk, prethreshold, and beyond. This questions the efficiency of the treatment strategy followed in the study. The images of the infants needing treatment were reviewed by another examiner before treatment probably implies that the findings of the screening physicians required reconfirmation. In such a case, babies labelled with severe ROP after erythropoietin injection should also have been reconfirmed by a retina specialist. Although the indication to give erythropoietin was under the discretion of the paediatrician, some details like baseline haemoglobin concentration and platelet count at the time of erythropoietin injection would have been more informative as they are known to affect the severity of ROP independent of erythropoietin. Reports say that effect of erythropoietin on ROP depends whether it was given at early or late post-natal life.4 So a similar division in the study could have given extra information.

The cumulative dose of erythropoietin received by neonate with mild ROP (3200 units) was more than those with severe disease (2750 units).To establish erythropoietin as a contributory cause, it is important for the cause to not only have statistical significance but also alter the effect on altering the cause with a proven dose–response relationship, which the study fails to show.


  1. Kandasamy Y, Kumar P, Hartley L . The effect of erythropoietin on the severity of retinopathy of prematurity. Eye (Lond) 2014; 28 (7): 814–818.

    CAS  Article  Google Scholar 

  2. Tobias JD, Leder M . Procedural sedation: a review of sedative agents, monitoring, and management of complications. Saudi J Anaesth 2011; 5 (4): 395–410.

    Article  Google Scholar 

  3. Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 2003; 121 (12): 1684–1694.

    Article  Google Scholar 

  4. Aher SM, Ohlsson A . Early versus late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2012; 10: CD004865.

    PubMed  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to T R Padhi.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Modi, R., Padhi, T. Comment on ‘The effect of erythropoietin on the severity of retinopathy of prematurity’. Eye 29, 149 (2015).

Download citation

  • Published:

  • Issue Date:

  • DOI:


Quick links